TipRanks
ME Therapeutics Holdings, Inc. (TSE:METX)
:METX
Canadian Market

ME Therapeutics Holdings, Inc. (METX) Stock Statistics & Valuation Metrics

10 Followers

Total Valuation

ME Therapeutics Holdings, Inc. has a market cap or net worth of C$84.14M. The enterprise value is C$51.18.
Market CapC$84.14M
Enterprise ValueC$51.18

Share Statistics

ME Therapeutics Holdings, Inc. has 30,049,494 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding30,049,494
Owned by Insiders―
Owned by Institutions―

Financial Efficiency

ME Therapeutics Holdings, Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover―
Inventory Turnover―

Valuation Ratios

The current PE Ratio of ME Therapeutics Holdings, Inc. is ―. ME Therapeutics Holdings, Inc.’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value―
Price to FCF0.00
Price to Operating Cash Flow―
PEG Ratio―

Income Statement

In the last 12 months, ME Therapeutics Holdings, Inc. had revenue of ― and earned -1.29M in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income-1.37M
Pretax Income―
Net Income-1.29M
EBITDA-1.29M
Earnings Per Share (EPS)―

Cash Flow

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―

Dividends & Yields

ME Therapeutics Holdings, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―

Stock Price Statistics

Beta1.23
52-Week Price Change-42.86%
50-Day Moving Average2.50
200-Day Moving Average2.60
Relative Strength Index (RSI)53.05
Average Volume (3m)965.00

Important Dates

ME Therapeutics Holdings, Inc. upcoming earnings date is Dec 2, 2026, After Close (Confirmed).
Last Earnings DateJun 26, 2026
Next Earnings DateDec 2, 2026
Ex-Dividend Date―

Financial Position

ME Therapeutics Holdings, Inc. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―

Taxes

In the past 12 months, ME Therapeutics Holdings, Inc. has paid ― in taxes.
Income Tax―
Effective Tax Rate―

Enterprise Valuation

ME Therapeutics Holdings, Inc. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―

Balance Sheet

ME Therapeutics Holdings, Inc. has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt―
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―

Margins

Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―

Analyst Forecast

The average price target for ME Therapeutics Holdings, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-5.48%

Scores

Smart ScoreN/A
AI Score―